

Supplementary Table 5. Subgroup Analysis on Risk of Bleeding Events Associated with NSAIDs or SSRIs Concomitant with NOACs

	NSAIDs		SSRIs	
	Crude OR (95% CI)	Adjusted OR (95% CI)*	Crude OR (95% CI)	Adjusted OR (95% CI)*
HAS-BLED score				
0–2 (case=279, control=10099)	1.00 (0.76–1.31)	1.50 (1.09–2.07)	1.75 (1.03–2.98)	1.87 (1.06–3.30)
3–8 (case=954, control=14561)	1.13 (1.00–1.29)	1.16 (1.00–1.33)	1.78 (1.40–2.26)	1.91 (1.48–2.47)
	<i>p</i> for interaction=0.95		<i>p</i> for interaction=0.17	
Age groups				
<75 years (case=467, control=7982)	1.21 (0.98–1.49)	1.16 (0.39–3.42)	1.44 (0.96–2.15)	1.13 (0.15–8.72)
75 years or older (case=766, control=16678)	1.40 (1.20–1.63)	2.59 (1.24–5.41)	2.28 (1.75–2.98)	4.36 (1.24–15.3)
	<i>p</i> for interaction=0.19		<i>p</i> for interaction=0.06	
Sex				
Male (case=569, control=11380)	1.66 (1.39–199)	1.69 (0.79–3.65)	1.38 (0.95–2.01)	0.54 (0.10–3.04)
Female (case=664, control=13280)	1.14 (0.97–135)	1.99 (0.80–4.97)	2.39 (1.82–3.13)	8.53 (2.09–34.7)
	<i>p</i> for interaction=0.03		<i>p</i> for interaction=0.02	
Episode status				
Incident episode (case=896, control=17920)	1.50 (1.30–1.73)	1.74 (1.49–2.03)	2.03 (1.57–2.62)	2.09 (1.59–2.75)
Prevalent episode (case=337, control=6740)	1.03 (0.81–1.31)	0.94 (0.73–1.22)	1.67 (1.09–2.56)	1.60 (0.98–2.48)
	<i>p</i> for interaction=0.003		<i>p</i> for interaction=0.43	

CI, confidence interval; OR, odds ratio; NSAIDs, non-selective non-steroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors; NOAC, non-vitamin K antagonist oral anticoagulant.

*Adjusted for demographic characteristics, comedications (NSAIDs or SSRIs, beta-blockers calcium channel blockers, angiotensin II receptor antagonists, statins, diuretics), and comorbidities (myocardial infarction, dementia, liver/renal disease).